Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thrombocytopenia 7 Lymphoma, Non-Hodgkin 5 Neoplasms 3 Multiple Myeloma 3 Hodgkin Disease 3 Purpura, Thrombocytopenic, Idiopathic 2 Purpura, Thrombocytopenic 2 Ovarian Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Solid Tumor 1 Sarcoma, Ewing 1 Pancreatic Neoplasms 1 Melanoma 1 Lymphoma, Mantle-Cell 1 Lymphoma 1 Lung Neoplasms 1 Leukemia, Monocytic, Acute 1 Leukemia, Lymphoid 1 Hematologic Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Chemotherapy-induced Thrombocytopenia 1 Breast Neoplasms 1

Interventions

pembrolizumab 287 Nivolumab 258 Ipilimumab 236 Cyclophosphamide 135 aldesleukin 134 Interleukin-2 104 Temozolomide 75 Dacarbazine 74 trametinib 70 Vemurafenib 69 fludarabine 68 dabrafenib 65 fludarabine phosphate 62 sargramostim 44 binimetinib 44 Radiosurgery 44 Biopsy 43 Paclitaxel 42 Bevacizumab 42 incomplete Freund's adjuvant 39 encorafenib 37 Radiotherapy 36 Cisplatin 36 CTLA-4 Antigen 36 atezolizumab 35 Carboplatin 35 Magnetic Resonance Spectroscopy 33 cobimetinib 32 Specimen Handling 31 Introns 30

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Melanoma × romiplostim × Clear all

NCT04427306 2023-09-15

Neoadjuvant T-VEC in High Risk Early Melanoma

University of California, Davis

Phase 2 Suspended

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡